Filing Flows › BridgeBio Pharma (BBIO) › Q1 2026
BridgeBio Pharma (BBIO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
BridgeBio Pharma (BBIO) reported revenue of $195M for the first quarter 2026 (Q1 2026), +67% from a year earlier and +26% from the quarter before. Operating margin was -54.5%, net loss $167M (85.6% of revenue).
BridgeBio Pharma, Q1 2026: revenue $195M (+67% year over year), operating margin -54.5%, net loss $167M, operating cash flow −$197M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $195M | +26% | +67% |
| Operating profit | −$106M | — | — |
| Net earnings | −$167M | — | — |
| Operating cash flow | −$197M | — | — |
What changed
Revenue was $194.5M in Q1 2026, up 67% year over year and up 26% from the previous quarter. Net product revenue was the largest line at 93% of revenue. Net product revenue added $143.9M year over year (up 392%), 185% of the total change. License and services revenue declined 94%.
Operating costs exceeded revenue by $106.0M, an operating margin of -54.5%. Total costs grew 36% against revenue growth of 67%. The fastest-growing cost line was Cost of revenue (+277%). The quarter ended with a net loss of $166.6M, narrower than the previous quarter's $194.6M loss. Minority interests bore $2.5M of it: to shareholders the quarter was a loss of $164.0M.
Operating cash flow was −$197.3M. Non-cash charges added back $1.2M of depreciation and amortization and $33.2M of share-based compensation. Working capital and other items used $65.2M. Capital expenditures of $69K exceeded it, leaving free cash flow of −$197.3M.
Questions
What was BridgeBio Pharma's revenue in the first quarter 2026?
BridgeBio Pharma (BBIO) reported revenue of $195M for the first quarter 2026 (Q1 2026), +67% from a year earlier and +26% from the quarter before.
Was BridgeBio Pharma profitable in the first quarter 2026?
Operating loss was $106M (-54.5% of revenue) and net loss $167M.
Source: BridgeBio Pharma 10-Q on SEC EDGAR.